According to the 2022 Chinese Expert Consensus on Immunotherapy for Advanced NSCLC with Driver Genes, for patients with extensive progression after resistance to EGFR-TKIs and in the absence of effective targeted treatments, the use of immune checkpoint inhibitors (ICIs) is recommended. Here, EGFR is linked to non-small cell lung carcinoma.